Objective To evaluate the therapeutic effect and safety of ultrasound-guided high-intensity focused ultrasound (USgHIFU) treatment on symptomatic uterine fibroids in Black women.
Introduction
Uterine fibroids are the most common benign pelvic tumours in pre-menopausal women. 1 They represent clonal expansion of individual myometrial cells and are the most important cause of menstrual and fertility disturbance, including menorrhagia, dysmenorrhea and pelvic compression symptoms, such as urinary frequency and constipation. 2 Uterine fibroids are symptomatic in 20-40% of reproductive age women, but it varies across races. 3 It has been found that the prevalence of uterine fibroids is three times more common among Black females than Caucasian females. [4] [5] [6] Traditional treatment of uterine fibroids is based on symptoms, size and location of the fibroids, and the woman's desire for fertility. Treatment methods include medical management, selective uterine artery embolization *Cai Zhang and Hayley Jacobson are joint first authors who contributed equally to this study.
(UAE), and surgical alternatives including myomectomy and hysterectomy. 7 Medical treatment is suitable for alleviating the symptoms, temporarily controlling fibroid growth and shrinking fibroid size. However, once the medication is stopped, recurrence of symptoms and regrowth of fibroids usually occurs within 3-6 months. 8 Hysterectomy is traditionally the main modality of curative treatment for women who have completed childbearing and are menopausal. However, this surgical operation is unsuitable for patients who wish to retain fertility or keep their uterus. Myomectomy is an option for women who want to preserve their uterus. Nevertheless, cumulative data has shown that there is a 12.4-15% recurrence risk at 12 months and 33% risk at 27 months after myomectomy.
9,10 Postoperative adhesions occur in 60% of cases; in some cases, uterine rupture during a subsequent pregnancy has been reported. 11, 12 Although UAE has been introduced as a minimally invasive treatment alternative to surgery, it has perioperative risks including allergic reaction to iodine contrast dye, incomplete uterine artery occlusion, and inappropriate embolisation of other organs. 13 Nowadays, ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablative therapy, a novel non-invasive surgical technique, has been considered a conservative treatment for women with symptomatic uterine fibroids wishing to keep their uterus. This process causes coagulative necrosis of the fibroid by thermal effect, with accurate localisation and no harm to adjacent structures; furthermore, it has the advantage of no bleeding or surgery needed, and no radiation or drug side effects. [14] [15] [16] Many studies have shown USgHIFU ablation is a safe and effective treatment for uterine fibroids. 14, 15 However, the subjects of most reports were either Asian or Caucasian. To the best of our knowledge, there are no studies examining the application of USgHIFU on Black woman. Therefore, the aim of our study is to evaluate the therapeutic effect and safety of USgHIFU used to treat symptomatic uterine fibroids in Black females.
Methods

Patients
From October 2015 to February 2016, 26 patients with symptomatic uterine fibroids were treated in this study. The fibroids were diagnosed by clinical examination and magnetic resonance (MR) imaging.
The eligibility of patients was determined by evaluations made by both referring gynaecologists and HIFU physicians. Inclusion criteria were: (1) patients were premenopausal; (2) patients had symptomatic fibroids requiring treatment but refused surgery; (3) a clinical uterine size of less than 20 weeks' gestation and a dominant fibroid of less than 15 cm in diameter; (4) patients could lie in a prone position for at least 1 hour and were able to communicate with the anaesthetist or physician easily during the procedure. Exclusion criteria were: (1) menstruating, pregnant or lactating women; (2) women with contraindications to MR imaging (allergic to contrast, metal foreign bodies in treatment area, e.g. IUCD, Filchi clips); (3) patients with suspected or confirmed uterine malignancy or ovarian tumours; (4) major co-morbidities; (5) abnormal Pap smear; (6) obesity (abdominal wall thickness greater than 60 mm).
Pre-and posttreatment MR imaging
All patients were required to undergo a pelvic contrastenhanced MR imaging examination (1.5 T TESLA, G.E., America) pretreatment and within 1 month posttreatment ( Figure 1 ). The number, size, volume, location and T2 signal intensity of fibroids and presence of enhancement (blood supply) after administration of gadolinium injection was recorded in pretreatment MR imaging. Non-perfused volume (NPV) was measured with contrast-enhanced posttreatment MR images to estimate fibroid necrosis volume. The ablation rate was also recorded, which was defined as NPV/fibroid volume 9 100%. All the MR images were assessed independently by two senior screening physicians.
Pretreatment preparation
Patients were requested to see a dietitian and were given clear instructions concerning diet preparation for bowel safety. A bland diet without fibre was required 3 days prior to HIFU treatment, followed by semi-liquid and liquid food over the next 2 days. After 12 hours of fasting, an enema was given on the morning of treatment. Shaving of lower abdominal hair was performed (range: umbilicus to upper margin of the pubic symphysis, left anterior axillary line to right anterior axillary line), followed by de-greasing process using 70% ethanol. At 30 minutes prior to treatment the skin was degassed using a vacuum device. Finally, for bowel safety, a degassed water balloon was placed on the abdominal wall to push the bowel out of the acoustic pathway. This balloon lies between the transducer in the machine and the abdominal wall.
HIFU ablation
In this study, HIFU treatment was performed using an USgHIFU system (JC200; Haifu Medical Technology Co., Chongqing, China). This system is integrated with a sonar device (MyLab 70; Esaote, Genova, Italy), providing realtime monitoring. Focused ultrasound energy (frequency of 1.0 MHz) was produced by a 20-cm-diameter transducer with a focal region of 8 9 3 9 3 mm. Three-dimensional movement of the transducer was achieved with a mechanical positioning device linked to the system. Patients were carefully positioned in a prone position on the treatment bed, with the abdominal wall immersed in degassed water. Conscious sedation was administered during the procedure to control the patients' reactions and prevent unnecessary body movement. Fentanyl (maximum, 200 lg), and dormicum (maximum, 2 mg) were used for sedation. Paracetamol (10 mg/ml) was used for pain relief. An infusion pump of oxytocin (1 IU/ml) was set at rate of 0.3 IU/minute to shrink blood vessels around and inside fibroids. During treatment, patients were requested to lie still and to report any discomfort, including burning of the skin, and lower abdominal, leg, sciatic or buttock pain. The USgHIFU ablation treatment was terminated in the presence of an obvious general or great grey-scale change inside the fibroid lesion.
Statistical analysis
SPSS software (SPSS 19.0, IBM, Chicago, IL, USA) was used for analyzing data. First, for statistics of probability distribution, the one-sample Kolmogorov-Smirnov test was used for each group of data. If the data feature was in the normal distribution, means AE SD was reported; if it had an abnormal distribution, median and interquartile range (P25-P75) was reported.
Results
Patients' demographic characteristics
As shown in Table 1 , 26 patients with 53 fibroids were enrolled in this study. The average age was 34.4 AE 6.2 years (range, 18-43). The mean weight of patients was 66.5 AE 12.0 kg (range, 44.0-88.0), with the average abdominal skin thickness of 16.6 AE 10.5 mm (range, 4.2-44.5). Among the 53 fibroids, 19 were located in anterior wall, 10 in the posterior wall, 14 in the lateral wall and 10 in the fundus. Ten of them were submucosal, 14 were intramural and 29 were subserosal. Based on MR imaging, the median volume of fibroids was 52.7 (interquartile range, 18.6-177.4) cm 3 . Based on the MRI T2 signal intensity, the majority of fibroids were hypo-intense (44 of 53). All the patients had fibroid-related symptoms, the most common being menorrhagia (76.9%), nulliparity/ infertility (73.1%) and dysmenorrhea (69.2%).
Evaluation of HIFU treatment
All the patients achieved successful HIFU ablation of the fibroids. Details of the procedure were as follows: median sonication power 399 W (interquartile range, 398.8-400.0); total energy 298.6 AE 169.3 kJ ( Table 2 ). The length of treatment time was 90.3 AE 43.3 minutes (range, 14.0-208.0) and the sonication time specifically to ablate fibroids was 774.0 AE 432.9 seconds (range, 190.0-2224.0). The mean ablation rate was 80.6 AE 9.7% (range, 46.5-94.5%). In all, 65.4% of fibroids (34/53) attained extensive greyscale change during the procedure (Figure 2) , and the rest attained general grey-scale change (34.6%, 18/53).
Adverse effects and complications
Under conscious sedation, all patients tolerated the treatment well. No severe complications were observed during or immediately after HIFU treatment. The most common adverse effects observed during the procedure were: mild pain in the treated area (lower abdomen) (69.2%), sciatic/ buttock pain (57.7%), burning skin (38.5%) and transient leg pain (34.6%) ( Table 3 ). These reported adverse effects disappeared within 3 days in most patients.
Discussion
For the last few decades, studies have documented an increased incidence of uterine fibroids in Black women. In the Caucasian population, uterine fibroids commonly present with symptoms between the ages of 35 and 45 years. 17 However, due to genetic and racial factors, women of Black origin tend to develop fibroids with more tumours and greater symptomatology at a younger age, usually in the third decade of life. 18 In this study, the average age of the patient was 34.4 AE 6.2 years, which confirmed the findings of previous studies. Furthermore, fibroids are common in nulliparous or infertile Black females. A Nigerian clinical research study reported that 44.4% and 31.9% of patients with fibroids were nulliparous and infertile, respectively. 18 Our study also showed similar results, in that 73.1% of patients complained of nulliparity or infertility. Because USgHIFU is a non-invasive local thermal ablation technique that allows the integrity of the uterus to be maintained, it is a successful treatment method for the management of symptomatic uterine fibroids and infertility prevalent in younger Black women. The concept of using an extracorporeal source of focused ultrasonic energy to induce coagulative necrosis in targeted tissue without damaging adjacent vital structures was first proposed by Lynn et al. in the 1940s. 19 Research on the use of focused ultrasound on tumours was further investigated during the 1980s and 1990s. The principle behind HIFU is to focus ultrasonic energy on a small area, causing protein denaturation and irreversible cell necrosis through a heating effect (above 60°C), cavitation and direct damage to tumour blood vessels at the focal spot. 20 USgHIFU includes a diagnostic ultrasound scanner, making it ideal for localisation and targeting. 21 The real-time imaging ability allows monitoring of both the efficacy and safety of focused ultrasound treatment. For efficacy evaluation, changes in grey-scale during treatment are well correlated with the volume of induced necrosis. In our study, all the fibroids successfully developed grey-scale change; around two-thirds had easily distinguishable, large grey-scale change (Table 2) . MR-guided HIFU is a subtype of this novel non-invasive technique. However, it is time-consuming; it is therefore not as efficient as USgHIFU and has a limited clinical application. In Zhang et al.'s report, 22 14, 16 Another factor related to treatment efficacy and efficiency was the T2 signal intensity of the fibroid upon MR screening. Peng's group 23 found that the signal intensity on T2 had a linear correlation with ultrasonic energy efficiency, influencing the relation between dosage and effectiveness of HIFU ablation. In radiopathology, a fibroid that is hypo-intense on T2 is typically composed of closely arranged cells, with abundant collagen fibres and poor blood supply; thus, ultrasonic energy can be easily absorbed and deposited in this type of fibroid. The majority of fibroids in our study were T2 hypo-intense (44/53), which strongly predicted the efficacy of USgHIFU ablation in Black women. Safety is another important concern for the USgHIFU treatment of uterine fibroids. As HIFU is a non-invasive treatment modality, common surgically related complications such as intraoperative bleeding, infection and visceral damage do not occur. In this study, patients reported lower abdominal pain, sciatic/buttock pain, burning skin and leg pain during HIFU sonication, and vaginal bleeding immediately after treatment. However, these HIFU-related adverse effects or complications were mild and transient, with a pain score of less than 4 points on the pain scale. In fact, the complications disappeared in a short time without any specific treatment. Previous clinical experience in other HIFU centres has shown that abdominal scars increased the risk of skin burns during HIFU treatment. Four patients in this study had surgical scars on the skin within the ultrasonic beam pathway. However, with careful skin preparation and appropriate pace of treatment (short sonication time, adequate interval between sonications, and frequent breaks for skin to cool) all four patients had successful HIFU treatment without any skin redness or blister formation. Severe complications reported by previous studies, such as bowel injury, haematuria and impairment of peripheral nerves were not observed in this study. Our results showed that HIFU treatment for Black women with symptomatic uterine fibroids could be well tolerated and had a satisfactory safety profile.
Limitations, including a small cohort of enrolled patients and lack of long-term follow up, should be taken into consideration in this study. Future studies require a larger sample size, more frequent follow ups (at 1, 6, 12 and 24 months) to measure fibroid size and calculate shrinkage rate, and to evaluate improvement of symptoms and quality of life. Pregnancy outcome posttreatment should also be followed up because a large proportion of our patients were nulliparous and infertile women.
In conclusion, this preliminary study is the first report to demonstrate that ultrasound-guided focused ultrasound treatment for uterine fibroids can be applied in Black females. Although further studies are needed to explore the long-term outcomes the results of our study have provided evidence that the use of USgHIFU to treat Black women with uterine fibroids is feasible and safe.
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